AI-generated from publicly available materials.EVERSANA has expanded its capabilities in the life sciences sector by acquiring Estima Scientific, a UK-based firm specializing in health economics and outcomes research (HEOR).
This acquisition allows EVERSANA to enhance its AI Agency platform, which focuses on utilizing advanced data science tools to expedite patient access to medications. Estima employs large language models and unique software to optimize workflows related to HEOR and health technology assessments, significantly reducing the time and effort typically required for tasks like literature reviews and economic modeling.
According to Estima's co-founder Tim Reason, the technology facilitates earlier evidence generation and market access submissions, thereby making it feasible for pharmaceutical companies to launch products in markets that would have previously been deemed commercially unviable. This aligns with EVERSANA's goal of helping clients demonstrate the clinical and economic value of their drugs more efficiently.
With a strong international client base, Estima's integration into EVERSANA's offerings underscores the company's commitment to leveraging AI in the pharmaceutical commercialization process. This strategic move follows a series of acquisitions aimed at consolidating EVERSANA's AI-powered solutions across the commercial value chain, emphasizing the growing importance of technology in the industry.